"糟得很"和"好得很"——聚焦企业医院转型中的高管心态

当转型后手中的权力即将随着医院剥离、重组而付之东流,能否做到泰山崩于前而不为所动?当新东家的到来将让你在所有同僚面前扬眉吐气,是否还能义正词严地拒绝他们的光荣策反?当进和退都意味着遭遇深渊,如何选择两种死亡中的任何一项必然?医院转型、重组、剥离对谁来说都不是一件轻松的事。在利益和权力的角逐中,有沧海横流的英雄本色,更有勾心斗角的人心真实……     

浅析我国台湾地区药害救济法及制度借鉴

目的 借鉴我国台湾地区的药害救济制度,探索我国大陆的药害救济制度.方法 详细解析我国台湾地区的药害救济法的立法背景、目的以及药害救济法的具体内容.结果与结论 这种制度对于我国大陆医药制度的改革和发展具有一定的借鉴和参照的价值.     

体外循环降温期不同氧分压对二尖瓣膜置换患者术后的影响

目的评价体外循环降温期不同的氧分压对二尖瓣置换患者术后的影响。方法75例二尖瓣置换术患者，按体外循环降温末期动脉血氧分压数，分成低氧组、常氧组和高氧组，记录体外循环结束后第1、8、16小时多巴胺用量。术后麻醉清醒时间和呼吸机辅助时间，同时记录患者的年龄、体重、体外循环时间、升主动脉阻断时间和左室射血分数。结果体外循环术后第1小时内，常氧组多巴胺用量明显小于低氧组和高氧组（P〈O．05），术后第8小时，常氧组多巴胺用量明显小于低氧组（P〈O．05）。术后麻醉清醒时间和呼吸机辅助时问各组问无显著性差异。结论二尖瓣置换术体外循环降温期，常氧分压氧合有利于术后早期患者心功能恢复。     

55例新生儿重度窒息产科原因分析

目的探讨新生儿重度窒息发生的产科原因,制定干预措施,提高产科质量。方法回顾性分析2003年1月~2004年12月我院55例新生儿重度窒息的相关因素。结果新生儿重度窒息为综合因素所致,胎儿高危因素为90·9%,分娩时高危因素为58·2%,母体高危因素为43·6%。结论提高产前检查质量,加强高危妊娠产前和产时的监护,综合分析可能发生新生儿窒息的高危因素,适时正确选择分娩方式是降低新生儿重度窒息和病死率的关键措施。     

Improved exposure of isolated perimembranous ventricular septal defects

We describe an alternative step in the transatrial approach to the repair of ventricular septal defects. We temporarily detach the chorda of the obscuring tricuspid valve from its attachment to the septum to expose the ventricular septal defect.     

纤溶酶原激活物抑制物-1与不稳定心绞痛的关系

目的:探讨纤溶酶原激活物抑制物-1(PAI-1)血浆抗原水平及其基因启动子-844G→A多态性与不稳定心绞痛(UAP)的关系。方法:UAP患者121例(UAP组)和冠状动脉造影正常者108例(对照组),以ELISA法测定其血浆PAI-1抗原水平。PCR扩增特定DNA片段,XhoI酶切和琼脂糖电泳确定基因型。结果:UAP组血浆PAI-1抗原水平为(68.15±45.29)μg/L,显著高于对照组的(53.39±20.62)μg/L(P<0.01)。血浆PAI-1抗原水平与冠状动脉病变支数呈正相关(r=0.139熏P<0.05),与血糖(Glu)、总胆固醇(TC)、低密度脂蛋白(LDL)正相关,r分别为0.147,0.151,0.144(P<0.05)。AA、AG、GG3种基因型在2组间分布差别无统计学意义,但A等位基因与较高的血浆PAI-1抗原水平有关。UAP组AA及AG基因型者血浆PAI-1抗原水平显著高于对照组。结论:PAI-1基因启动子-844G→A基因多态性与UAP无关,但A等位基因携带者存在较高的PAI-1血浆抗原水平。     

Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.

Monoclonal antibody (mAb) 806 is a novel epidermal growth factor receptor (EGFR) antibody with significant antitumor activity that recognizes a mutant EGFR commonly expressed in glioma known as delta2-7 EGFR (de2-7 EGFR or EGFRvIII) and a subset of the wild-type (wt) EGFR found in cells that overexpress the receptor. We have used two human xenograft mouse models to examine the efficacy of mAb 806 in combination with mAb 528, a prototypical anti-EGFR antibody with similar specificity to cetuximab. Treatment of nude mice, bearing s.c. or i.c. tumor human xenografts expressing the wt or de2-7 EGFR, with mAbs 806 and 528 in combination resulted in additive and in some cases synergistic, antitumor activity. Interestingly, mAb 528 was also effective against xenografts expressing the ligand independent de2-7 EGFR when used as a single agent, showing that its antitumor activity is not merely mediated through inhibition of ligand binding. When used as single agents, neither mAbs 806 or 528 induced down-regulation of the de2-7 EGFR either in vitro or in vivo. In contrast, the combination of antibodies produced a rapid and dramatic decrease in the total cell surface de2-7 EGFR both in vitro and in xenografts. Consistent with this decrease in total cell surface de2-7 EGFR, we observed up-regulation of the cell cycle inhibitor p27(KIP1) and a decrease in tumor cell proliferation as measured by Ki-67 immunostaining when the antibodies were used in combination in vivo. Thus, mAb 806 can synergize with other EGFR-specific antibodies thereby providing a rationale for its translation into the clinic.     

Differential expression of CXCR4 is associated with the metastatic potential of human non-small cell lung cancer cells.

PURPOSE: To evaluate the relation between CXCR4 expression and the presence of metastatic disease in human non-small cell lung cancer (NSCLC) patients and investigate whether modulation of CXCR4 expression could serve as a potential pathway in preventing metastasis of NSCLC. EXPERIMENTAL DESIGN: CXCR4 expression in 36 patients with NSCLC and 10 normal lung tissues was detected by real-time PCR and immunohistochemistry. CXCR4 expression in two human NSCLC clones (95C and 95D) with different metastatic potential was determined by real-time PCR and flow cytometry. 95C and 95D cells were transfected with the plasmid DNA containing CXCR4 coding gene or CXCR4 antisense nucleotide fragment, respectively, and the effects on in vitro cell migration, invasion, and adhesion and in vivo metastasis were measured. RESULTS: Up-regulated expression of CXCR4 was detected in 34 tumors, which were further divided into 17 high expression cancers and 17 low expression cancers by their staining intensities. High CXCR4 tumors (13 of 17) were more prone to clinical metastasis in comparison with low expression tumors. CXCR4 was differentially expressed in 95C and 95D cells with low or high metastatic potential, and the surface expression of CXCR4 were 50% up-regulated or down-regulated following the stable transfection. The metastatic potential of NSCLC in vitro, such as migration, invasion, and adhesion, were significantly enhanced or impaired. In addition, neutralizing the interactions of stromal cell-derived factor-1/CXCR4 in vitro with CXCR4-specific antibodies inhibited the CXCR4-dependent migration, invasion, and adhesion. Furthermore, s.c. inoculation of lung cancer cells with low expression of CXCR4 in nude mice showed 0- to 2-fold decrease in lung metastatic foci than that with high expression of CXCR4. CONCLUSIONS: Differential expression of CXCR4 is associated with the metastatic potential of human NSCLC, raising the possibility that blockade of CXCR4/stromal cell-derived factor-1 interaction may lead the way to design novel therapeutic tools for the treatment of metastatic NSCLC patients.     

聚维酮碘泡腾颗粒的制备和质量控制

目的:研制聚维酮碘泡腾颗粒.方法:以溶液pH、颗粒性状及溶化性为指标筛选处方及工艺,并制定质量标准.结果:以酒石酸、碳酸氢钠为泡腾剂,聚维酮醇液作黏合剂制得的聚维酮碘泡腾颗粒符合临床用药要求.结论:本制剂工艺简便,质量可控.     

超声及磁共振检查对脊髓神经管畸形胎儿产前诊断的应用综述

近年来产前超声和胎儿磁共振成像技术取得了快速的发展,这些技术能够在胎儿期对脊髓神经管畸形做出超早期诊断及预后评估.本文介绍产前超声及胎儿磁共振技术在不同类型脊髓神经管畸形的产前诊断和预后评估中的优缺点,总结具有实用价值的诊断和评估方法,旨在提高临床医生为孕妇提供产前咨询建议的能力.